Sone Capital Management’s Standard BioTools LAB Stock Holding History

Sone Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.62M	Buy	+1,766,781	New	+$2.14M	0.14%	95

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Sone Capital Management's LAB Position: Q1 2026 in Review

Sone Capital Management opened a new position in Standard BioTools (LAB) in Q1 2026: 1,766,781 shares worth $1.62M. The stake represents 0.14% of the portfolio and ranks #95 among its holdings.

155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Sone Capital Management held 1,766,781 shares of Standard BioTools worth $1.62M as of Q1 2026.
Standard BioTools was a new Sone Capital Management position in Q1 2026.
Standard BioTools made up 0.14% of Sone Capital Management's portfolio in Q1 2026, its #95 holding.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Sone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.